newsfilter
← Latest News
GlobeNewswire·

NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial

NTHI
  • NeOnc Technologies Holdings CEO Amir Heshmatpour purchased 70,000 shares in the open market, raising his total recent buys to 150,000 shares.
  • The latest transactions totaled approximately $294,500 at an average price of $4.207 per share, with individual prices ranging from $4.00 to $4.49.
  • Combined with prior purchases of 80,000 shares, Heshmatpour committed approximately $563,582 between November 5–11, 2026.
  • These purchases increased Heshmatpour's direct holdings to 3,333,000 shares, separate from indirect positions.
  • The FDA granted a Type B End-of-Phase meeting for early January 2027 to discuss a potential accelerated approval pathway for intranasal NEO100.
  • NeOnc seeks feedback on using clinical evidence for recurrent or progressive IDH-mutant grade 4 astrocytoma approval.
  • The company aims to agree on the design of NEO100-012, a Phase 3 trial comparing NEO100 to standard-of-care chemotherapy with overall survival as the primary endpoint.
  • Roth MKM reaffirmed its Buy rating and $20 price target for NeOnc stock.
  • On November 13, 2026, NeOnc will present updated NEO100 Phase 1/2a results and NEO212 Phase 1 data at the Society for Neuro-Oncology Annual Meeting.
  • An FDA End-of-Phase 1 meeting for NEO212 is scheduled for November 17, 2026, to address Phase 2 development plans.
  • Short interest in NTHI rose to approximately 921,000 shares as of October 30, 2026, up from 876,682 shares on October 15.
  • InvestorsTape.com disclosed it received compensation for press coverage of NeOnc Technologies Holdings.
Company
Investors Tape and NeOnc
Keywords
Nasdaq:NTHI, Investors Tape and NeOnc, $NTHI, Bullish, Insider buying, brain cancer, FDA